(via NewsDirect)
By
Over the last 20 years, the pharmaceutical syringe operational model has shifted from the use of glass vials and bulk disposable syringes to next-generation prefillable syringes, increasing prefillables from 15% to 85% share. This has contributed to market expectations of
Prefillable or ready-to-use syringes drive down the total cost of ownership for pharmaceutical companies by simplifying the supply chain and reducing product waste. Key advantages of prefillable syringe systems address contamination issues for the broader healthcare market, improving drug shelf life while reducing unnecessary packaging, and providing best-in-class solutions to get drugs to patients more efficiently.
Through its recent product launch announcement, Sharps is addressing multiple problems in the syringe system market by modernizing the prefillable space with its polymer-based product line. The Company has developed a high-quality alternative solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution as compared to traditional glass syringe systems. These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long-term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which function to eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors.
Sharps is also making a silicone-free prefillable product that addresses silicone interaction issues for the broader healthcare market. Currently, syringes are commonly made with medical-grade silicone, but utilizing siliconeand can result in drug contamination, adding a need for costly inspections every time syringes are filled. Sharps’ silicone-free solution removes the risk of interaction with biologics and eliminates the need for product inspections and potential product waste issues.
Major Partnership with Nephron Pharmaceuticals Advances Manufacturing and Product Launches
Though Sharps is currently a pre-revenue company, the Company is transitioning from a research and development company into commercial operations through a major partnership signed with
Initial demand will be supported by manufacturing capacity of 20+ million units, with additional capacities that can be scaled by 2025 with an additional 100 million units annually. Products will be manufactured utilizing state-of-the-art injection molding technologies with highly automated assembly lines. The products will be sterilized using an eco-friendly clean sterilization option easily adaptable for the pharmaceutical market. Sharps' systems will utilize ISO Standard Nest and Tubs that will be compatible with existing fill-finish technologies to provide a drop-in solution for the industry. Sharps believes this increased production capacity and distribution will allow it to fill a growing market that is looking for innovative prefillable solutions.
The partnership is part of Nephron’s InjectEZ program to increase manufacturing out of its
To learn more about
This article was originally published on Benzingahere.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
adam@tradigitalir.com
Company Website
http://sharpstechnology.com/
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source